{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=2", "query": { "intervention": "Placebo Once Weekly", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-20T21:06:58.815Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07745504", "title": "A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Overweight", "Obesity" ], "interventions": [ { "name": "Cagrilintide", "type": "DRUG" }, { "name": "Placebo cagrilintide", "type": "DRUG" }, { "name": "Placebo semaglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2026-08-04", "completion_date": "2027-07-06", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-20T21:06:58.815Z", "location_count": 11, "location_summary": "Conyers, Georgia • Honolulu, Hawaii • Oak Park, Illinois + 8 more", "locations": [ { "city": "Conyers", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Oak Park", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07745504" }, { "nct_id": "NCT03243552", "title": "Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ASD" ], "interventions": [ { "name": "L-DOPA versus Placebo", "type": "DRUG" }, { "name": "Social Skills Training", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "13 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "13 Years to 30 Years" }, "enrollment_count": 56, "start_date": "2017-06-01", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-09-20T21:06:58.815Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03243552" }, { "nct_id": "NCT00675714", "title": "Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Burns" ], "interventions": [ { "name": "Stable Isotope Infusion Study", "type": "PROCEDURE" }, { "name": "Collection of blood and tissues", "type": "PROCEDURE" }, { "name": "Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI", "type": "PROCEDURE" }, { "name": "Humatrope", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Oxandrolone", "type": "DRUG" }, { "name": "Propranolol", "type": "DRUG" }, { "name": "Oxandrolone and propranolol combined", "type": "DRUG" }, { "name": "Humatrope and propranolol combined", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Exercise--Hospital supervised intensive exercise program", "type": "BEHAVIORAL" }, { "name": "Home exercise program", "type": "BEHAVIORAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BEHAVIORAL" ], "sponsor": "The University of Texas Medical Branch, Galveston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "80 Years", "sex": "ALL", "summary": "Up to 80 Years" }, "enrollment_count": 1126, "start_date": "2004-01", "completion_date": "2019-07-15", "has_results": false, "last_update_posted_date": "2019-11-29", "last_synced_at": "2026-09-20T21:06:58.815Z", "location_count": 1, "location_summary": "Galveston, Texas", "locations": [ { "city": "Galveston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00675714" }, { "nct_id": "NCT03131687", "title": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "tirzepatide", "type": "DRUG" }, { "name": "Dulaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 318, "start_date": "2017-05-24", "completion_date": "2018-08-01", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-09-20T21:06:58.815Z", "location_count": 35, "location_summary": "Mobile, Alabama • Anaheim, California • Fresno, California + 30 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03131687" }, { "nct_id": "NCT01394952", "title": "Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Disease", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Dulaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 9901, "start_date": "2011-07-22", "completion_date": "2018-08-21", "has_results": true, "last_update_posted_date": "2019-10-08", "last_synced_at": "2026-09-20T21:06:58.815Z", "location_count": 51, "location_summary": "Mobile, Alabama • Pell City, Alabama • Phoenix, Arizona + 48 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01394952" }, { "nct_id": "NCT02410343", "title": "Study of TV-1106 in Growth Hormone-Deficient Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Growth Hormone Deficiency" ], "interventions": [ { "name": "TV-1106", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2015-04-30", "completion_date": "2015-12-31", "has_results": true, "last_update_posted_date": "2022-01-24", "last_synced_at": "2026-09-20T21:06:58.815Z", "location_count": 25, "location_summary": "Artesia, California • Fountain Valley, California • Miami, Florida + 15 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02410343" }, { "nct_id": "NCT00260143", "title": "Testosterone and Physical Function in HIV+ Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Associate Weight Loss" ], "interventions": [ { "name": "Testosterone enanthate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 61, "start_date": "2003-05", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2018-03-09", "last_synced_at": "2026-09-20T21:06:58.815Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00260143" }, { "nct_id": "NCT02070978", "title": "Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Atacicept 75 mg", "type": "DRUG" }, { "name": "Atacicept 150 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2014-07-29", "completion_date": "2018-02-09", "has_results": true, "last_update_posted_date": "2019-03-21", "last_synced_at": "2026-09-20T21:06:58.815Z", "location_count": 23, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Beverly Hills, California + 17 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fontana", "state": "California" }, { "city": "San Leandro", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02070978" }, { "nct_id": "NCT03534284", "title": "Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Insomnia", "End Stage Renal Disease" ], "interventions": [ { "name": "Cognitive Behavioral Therapy for Insomnia", "type": "BEHAVIORAL" }, { "name": "Trazodone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2018-09-19", "completion_date": "2022-11-17", "has_results": true, "last_update_posted_date": "2024-02-05", "last_synced_at": "2026-09-20T21:06:58.815Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03534284" }, { "nct_id": "NCT01041274", "title": "DECIFER: Depression and Citalopram In First Episode Recovery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizophreniform Disorder" ], "interventions": [ { "name": "Citalopram", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Psychoeducation", "type": "BEHAVIORAL" }, { "name": "Cognitive Behavioral Therapy (CBT)", "type": "BEHAVIORAL" }, { "name": "Functional Magnetic Resonance Imaging (fMRI)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "16 Years to 40 Years" }, "enrollment_count": 95, "start_date": "2010-01", "completion_date": "2018-03-26", "has_results": true, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-09-20T21:06:58.815Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01041274" } ] }